FDA Determines Regulatory Review Period for NULIBRY Patent Extension Application

Summary

The U.S. Food and Drug Administration (FDA) has published a notice determining the regulatory review period for NULIBRY, a human drug product, in response to a patent extension application submitted to the U.S. Patent and Trademark Office (USPTO).